Tuberculosis

Evaluation of a lateral-flow nanoparticle fluorescence assay for …: Ingenta Connect

BACKGROUND: Programmatic management of TB infection is a critical component of the WHO End TB Strategy. Interferon-gamma release assays (IGRAs) overcome some limitations of the tuberculin skin test, but implementation of IGRA testing in low-resource settings is challenging.
METHODS:
In this feasibility study, we evaluated performance of a novel digital lateral-flow assay, the QIAreach® QuantiFERON® TB (QIAreach-QFT) test, against the QuantiFERON®-TB Gold Plus (QFT-Plus) assay. A population with a mix of risk factors for TB
infection (111 donors) were sampled over multiple days. A total of 207 individual blood samples were tested according to the manufacturer´s instructions.
RESULTS: The overall percentage agreement was 95.6% (two-sided 95% CI 91.8 98), with a positive percentage agreement
(i.e., sensitivity) of 100% (95% CI 94.7 100) and a negative percentage agreement (i.e., specificity) of 95.6% (95% CI 90.6 98.4). All QFT-Plus positive specimens with TB1-Nil and TB2-Nil values less than 1 IU/ml tested positive on QIAreach-QFT.
CONCLUSIONS: QIAreach
QFT is a deployable, accurate testing solution for decentralised testing. It has the potential to overcome key hurdles for TB infection screening in high-burden settings thus helping to achieve the WHO End TB programme goals.

No Reference information available – sign in for access.

No Supplementary Data.

No Article Media

No Metrics

Keywords:
IGRA;
QIAreach QFT;
QuantiFERON;
TB infection;
validation

Document Type: Research Article

Affiliations:
1:
Qiagen Inc, Germantown, MD, USA
2:
Qiagen Manchester Ltd, Manchester, UK
3:
Former Qiagen employee
4:
Ellume Limited, East Brisbane, QLD, Australia
5:
Qiagen Manchester Ltd, Manchester, UK, Imperial College, London, UK

Publication date:
01 November 2021

More about this publication?

  • The International Journal of Tuberculosis and Lung Disease (IJTLD) is for clinical research and epidemiological studies on lung health, including articles on TB, TB-HIV and respiratory diseases such as COVID-19, asthma, COPD, child lung health and the hazards of tobacco and air pollution. Individuals and institutes can subscribe to the IJTLD online or in print – simply email us at [email protected] for details.

    The IJTLD is dedicated to understanding lung disease and to the dissemination of knowledge leading to better lung health. To allow us to share scientific research as rapidly as possible, the IJTLD is fast-tracking the publication of certain articles as preprints prior to their publication. Read fast-track articles.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites

Source Link


DISCLAIMER

This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.

All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.

This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.

Please see our Disclaimer for more information.

odiseases.com

diseases, diagnosis and treatment methods, drugs and their side effects on this site. online diseases, diagnosis and treatment methods

Related Articles

Back to top button
%d bloggers like this: